
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell human dataset derived from breast cancer tissue, we will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **ERBB2 (HER2)**: A member of the epidermal growth factor receptor (EGFR) family, often overexpressed in certain breast cancer subtypes, particularly HER2-positive breast cancer.<br>- **GRB7**: An adaptor protein that interacts with receptor tyrosine kinases like ERBB2, involved in signal transduction pathways that promote cell proliferation and survival.<br>- **MDM2**: A negative regulator of the p53 tumor suppressor, often amplified in cancers, contributing to tumorigenesis.<br>- **HSPB1 (HSP27)**: A heat shock protein involved in stress response, apoptosis inhibition, and cytoskeletal stabilization, often upregulated in cancer cells.<br>- **SQLE (Squalene Epoxidase)**: An enzyme involved in cholesterol biosynthesis, often upregulated in cancer cells, contributing to cell proliferation.<br>- **STARD3**: A cholesterol transporter associated with ERBB2 amplicon, often co-amplified with ERBB2 in breast cancer.<br><br>### Step 2: List the Key Cell Type Markers<br>- **ERBB2 (HER2)**: A key marker for HER2-positive breast cancer cells.<br>- **GRB7**: Often co-amplified with ERBB2 in HER2-positive breast cancer.<br>- **TFAP2B**: A transcription factor associated with luminal breast cancer subtypes.<br>- **APOD (Apolipoprotein D)**: Associated with lipid metabolism, often expressed in breast cancer cells.<br>- **KCNJ3 (GIRK1)**: A potassium channel subunit, sometimes associated with breast cancer cell signaling.<br>- **HES1**: A transcription factor involved in Notch signaling, often implicated in cancer stem cell maintenance and differentiation.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas, CellMarker, and literature on breast cancer, we can confirm that markers like ERBB2, GRB7, and STARD3 are strongly associated with HER2-positive breast cancer cells. TFAP2B and APOD are more associated with luminal subtypes, while HES1 is linked to cancer stem cell-like properties.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of ERBB2, GRB7, and STARD3, the most probable general cell type is **HER2-positive breast cancer cells**.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **HER2-Positive Breast Cancer Cells**: Given the high expression of ERBB2, GRB7, and STARD3, this is the most likely subtype.<br>2. **Luminal B Breast Cancer Cells**: TFAP2B and APOD suggest a luminal subtype, possibly Luminal B, which can also express HER2.<br>3. **Cancer Stem Cell-Like Subtype**: The presence of HES1 suggests a potential cancer stem cell-like phenotype within the tumor.<br><br>The most likely subtype based on the markers is **HER2-Positive Breast Cancer Cells**.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset indicates that the cell cluster is most likely composed of HER2-positive breast cancer cells. This conclusion is supported by the high expression of ERBB2, GRB7, and STARD3, which are key markers for this subtype. Additionally, the presence of markers like TFAP2B and APOD suggests a potential overlap with luminal subtypes, while HES1 indicates a possible cancer stem cell-like phenotype.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the identified cell type. Here's the breakdown:<br><br>1. **Marker Consistency**: <br>   - The key functional markers and cell type markers mentioned in the annotation (ERBB2, GRB7, MDM2, HSPB1, SQLE, STARD3, TFAP2B, APOD, KCNJ3, HES1) are all present in the provided marker list.<br>   - The markers ERBB2, GRB7, and STARD3 are strongly associated with HER2-positive breast cancer, which aligns with the annotation of HER2-positive breast cancer cells.<br><br>2. **Mixed Cell Type Consideration**:<br>   - The annotation acknowledges the potential presence of mixed cell types, such as Luminal B breast cancer cells and cancer stem cell-like subtypes, supported by markers like TFAP2B, APOD, and HES1.<br>   - The presence of these markers suggests a possible overlap with luminal subtypes and cancer stem cell-like phenotypes, which is appropriately flagged for further investigation.<br><br>Overall, the annotation is well-supported by the marker list and considers the possibility of mixed cell types, making it a comprehensive and accurate analysis.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">HER2-Positive Breast Cancer Cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Luminal B Breast Cancer Cells</li><li>Cancer Stem Cell-Like Subtype</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">90</div>
                        <div class="scoring-content">
                            The annotation results provided demonstrate a strong understanding of the single-cell data derived from breast cancer tissue. The analysis correctly identifies the main cell type as HER2-positive breast cancer cells, which is well-supported by the presence of key markers such as ERBB2, GRB7, and STARD3. These markers are indeed critical for identifying HER2-positive subtypes, and their prominence in the list justifies the primary annotation.<br><br>The annotation also considers the presence of other potential subtypes, such as Luminal B breast cancer cells and cancer stem cell-like subtypes, indicated by markers like TFAP2B, APOD, and HES1. This shows a balanced approach, acknowledging the complexity and heterogeneity of breast cancer tissues. The inclusion of these subtypes suggests a comprehensive view of the cell populations, which is crucial for understanding the tumor microenvironment.<br><br>However, there are a few areas where the analysis could be improved. While the annotation does a good job of identifying the main cell type and potential subtypes, it could benefit from a more detailed discussion of the rank and relative importance of each marker. For instance, while ERBB2 is a key marker, the analysis could have further emphasized the significance of its position in the list relative to other markers. Additionally, the annotation could explore the potential roles of other markers in the list that were not discussed, which might provide further insights into the cell populations.<br><br>Overall, the annotation is scientifically accurate and provides a comprehensive view of the cell types present, with a good balance in the use of different markers. There are no obvious misclassifications, and the analysis captures the general picture effectively.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    